These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22544507)

  • 1. Molecular therapies for tuberous sclerosis and neurofibromatosis.
    Franz DN; Weiss BD
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):294-301. PubMed ID: 22544507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
    Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
    Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.
    Neuman NA; Henske EP
    EMBO Mol Med; 2011 Apr; 3(4):189-200. PubMed ID: 21412983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R; Coniglio A; Garaci F; Curatolo P
    Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
    Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
    Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
    Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
    Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
    Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
    Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
    Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
    J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.